Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128


A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.

Qian J, Chen H, Ji X, Eisenberg R, Chakravarthy AB, Mayer IA, Massion PP.

Sci Rep. 2017 Apr 7;7:45828. doi: 10.1038/srep45828.


ZNF503/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression.

Shahi P, Wang CY, Lawson DA, Slorach EM, Lu A, Yu Y, Lai MD, Gonzalez Velozo H, Werb Z.

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3169-3174. doi: 10.1073/pnas.1701690114. Epub 2017 Mar 3.


Contextual Refinement of Regulatory Targets Reveals Effects on Breast Cancer Prognosis of the Regulome.

Andrews E, Wang Y, Xia T, Cheng W, Cheng C.

PLoS Comput Biol. 2017 Jan 19;13(1):e1005340. doi: 10.1371/journal.pcbi.1005340. eCollection 2017 Jan.


Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P.

Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. doi: 10.1158/1078-0432.CCR-15-2851. Epub 2016 Oct 4.


EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.

Katsyv I, Wang M, Song WM, Zhou X, Zhao Y, Park S, Zhu J, Zhang B, Irie HY.

Oncotarget. 2016 Oct 25;7(43):69592-69605. doi: 10.18632/oncotarget.11870.


Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.

Tominaga K, Shimamura T, Kimura N, Murayama T, Matsubara D, Kanauchi H, Niida A, Shimizu S, Nishioka K, Tsuji EI, Yano M, Sugano S, Shimono Y, Ishii H, Saya H, Mori M, Akashi K, Tada KI, Ogawa T, Tojo A, Miyano S, Gotoh N.

Oncogene. 2017 Mar 2;36(9):1276-1286. doi: 10.1038/onc.2016.293. Epub 2016 Aug 22.


ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.

Wrobel K, Zhao YC, Kulkoyluoglu E, Chen KL, Hieronymi K, Holloway J, Li S, Ray T, Ray PS, Landesman Y, Lipka AE, Smith RL, Madak-Erdogan Z.

Mol Endocrinol. 2016 Oct;30(10):1029-1045. Epub 2016 Aug 17.


The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.

Cockburn JG, Hallett RM, Gillgrass AE, Dias KN, Whelan T, Levine MN, Hassell JA, Bane A.

BMC Cancer. 2016 Jul 28;16:555. doi: 10.1186/s12885-016-2501-0.


Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis.

Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF, Brown BD, Gaspar-Maia A, Bernstein E.

Cell Rep. 2016 Jul 12;16(2):472-86. doi: 10.1016/j.celrep.2016.06.002. Epub 2016 Jun 23.


Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT.

Mitra S, Federico L, Zhao W, Dennison J, Sarkar TR, Zhang F, Takiar V, Cheng KW, Mani S, Lee JS, Mills GB.

Oncotarget. 2016 Jun 28;7(26):40252-40265. doi: 10.18632/oncotarget.9730.


Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.

Huang NS, Chi YY, Xue JY, Liu MY, Huang S, Mo M, Zhou SL, Wu J.

Oncotarget. 2016 Jun 21;7(25):37957-37965. doi: 10.18632/oncotarget.9364.


Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.

Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, Chiari R, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L.

Oncotarget. 2016 May 24;7(21):30561-74. doi: 10.18632/oncotarget.8723.


Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE.

Carmona G, Perera U, Gillett C, Naba A, Law AL, Sharma VP, Wang J, Wyckoff J, Balsamo M, Mosis F, De Piano M, Monypenny J, Woodman N, McConnell RE, Mouneimne G, Van Hemelrijck M, Cao Y, Condeelis J, Hynes RO, Gertler FB, Krause M.

Oncogene. 2016 Sep 29;35(39):5155-69. doi: 10.1038/onc.2016.47. Epub 2016 Mar 21.


Targeting the RB-E2F pathway in breast cancer.

Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LF, Bernards R.

Oncogene. 2016 Sep 15;35(37):4829-35. doi: 10.1038/onc.2016.32. Epub 2016 Feb 29. Review.


Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome.

Luo L, McGarvey P, Madhavan S, Kumar R, Gusev Y, Upadhyay G.

Oncotarget. 2016 Mar 8;7(10):11165-93. doi: 10.18632/oncotarget.7163.


Microenvironment and endocrine resistance in breast cancer: Friend or foe?

Recouvreux S, Sampayo R, Bessone MI, Simian M.

World J Clin Oncol. 2015 Dec 10;6(6):207-11. doi: 10.5306/wjco.v6.i6.207.


Gene-expression signature functional annotation of breast cancer tumours in function of age.

Jézéquel P, Sharif Z, Lasla H, Gouraud W, Guérin-Charbonnel C, Campion L, Chrétien S, Campone M.

BMC Med Genomics. 2015 Nov 23;8:80. doi: 10.1186/s12920-015-0153-6.


Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.

Cai H, Li X, Li J, Ao L, Yan H, Tong M, Guan Q, Li M, Guo Z.

Oncotarget. 2015 Dec 29;6(42):44593-608. doi: 10.18632/oncotarget.6260.


Highly informative marker sets consisting of genes with low individual degree of differential expression.

Galatenko VV, Shkurnikov MY, Samatov TR, Galatenko AV, Mityakina IA, Kaprin AD, Schumacher U, Tonevitsky AG.

Sci Rep. 2015 Oct 8;5:14967. doi: 10.1038/srep14967.

Supplemental Content

Support Center